Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 4/20 | 0.57 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.57 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.57 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.56 |
| ▸ | P2RY1 | P47900 | 8/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.53 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.53 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.51 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.51 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.51 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21136548 | 1.00 | P2RX1 (0.57) | P2RX1P2RX3P2RX4P2RX2P2RY1 | |
| SCHEMBL22224903 | 0.90 | P2RX1 (0.57) | P2RX1P2RX3P2RX4P2RX2P2RY1 | |
| SCHEMBL21136233 | 0.89 | P2RY1 (0.49) | P2RX1P2RX3P2RX4P2RX2P2RY1 | |
| SCHEMBL21136236 | 0.89 | P2RY1 (0.49) | P2RX1P2RX3P2RX4P2RX2P2RY1 | |
| SCHEMBL23760974 | 0.88 | P2RX1 (0.53) | P2RX1P2RX3P2RX4P2RX2P2RY1 | |
| SCHEMBL21137183 | 0.88 | P2RX1 (0.53) | P2RX1P2RX3P2RX4P2RX2P2RY1 | |
| SCHEMBL21137187 | 0.88 | P2RX1 (0.53) | P2RX1P2RX3P2RX4P2RX2P2RY1 | |
| SCHEMBL23760933 | 0.83 | P2RX3 (0.56) | P2RX1P2RX3P2RX4P2RX2P2RY1 | |
| SCHEMBL22224908 | 0.82 | P2RX1 (0.62) | P2RX1P2RX3P2RX4P2RX2P2RY1 | |
| SCHEMBL22224904 | 0.81 | P2RX1 (0.59) | P2RX1P2RX3P2RX4P2RX2P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10946033-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | Atea Pharmaceuticals, Inc. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190201433-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946033-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | NSUN2, ADAR, NSUN3 | P2RX1 205/4885P2RX3 199/4885P2RX4 212/4885 |
| US-20190201433-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | P2RX1 208/4885P2RX3 204/4885P2RX4 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.